Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids

PHASE2CompletedINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

March 31, 2007

Study Completion Date

March 31, 2007

Conditions
Uterine Fibroids
Interventions
DRUG

12.5 mg Proellex

12.5 mg Proellex administered orally daily

DRUG

25 mg Proellex

25 mg Proellex administered orally daily

DRUG

Placebo

Administered orally daily

Trial Locations (16)

29201

SC Clinical Research Center, Columbia

33143

Miami Research Associates, Women's Health Studies, Miami

33437

Visions Clinical Research, Boynton Beach

33607

Insignia Clinical Research (Tampa Bay Women's Center), Tampa

35235

Alabama Clinical Therapeutics, LLC, Birmingham

77030

Advances in Health Inc., Houston

77054

Obstetrical & Gynecolgical Associates, PA (OGA), Houston

80218

Downtown Women's Health Care, Denver

85015

Women's Health Research, Phoenix

85032

Arizona Wellness Centre for Women, Phoenix

85712

Visions Clinical Research Tuscon, Tuscon

89106

Caring for Women, Las Vegas

89128

Affiliated Clinical Research, Inc., Las Vegas

92108

Medical Centre for Clinical Research, San Diego

92123

Women's Health Care, Inc., San Diego

98105

Women's Clinical Research Centre, Seattle

All Listed Sponsors
lead

Repros Therapeutics Inc.

INDUSTRY

NCT00882258 - Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids | Biotech Hunter | Biotech Hunter